Patients characteristics associated with better glycemic response to teneligliptin and metformin therapy in type 2 diabetes: a retrospective study

Gadge, Pradeep; Gadge, Roshani P.; Paralkar, Nikita D.

doi:10.18203/2349-3933.ijam20181082

Cited by 3 publications

(2 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In present study, group-A patients who were treated with metformin and glimepiride had shown a significant decline in mean FPG, PPG and HbA1c levels, similar results were found in another study 10 . There was significant reduction in mean FPG, PPG and HbA1c observed in group B patients who received metformin and teneligliptin (p<0.05), which is in line with previous studies 11,12 .…”

Section: Discussionsupporting

confidence: 92%

Efficacy Of Dual Drug Therapy In Type-2 Diabetes Mellitus Patients Uncontrolled With Metformin Monotherapy (2023)

2023

jcdr

View full text Add to dashboard Cite

Type-2 Diabetes mellitus (type-2DM) is a multifactorial metabolic disorder, characterized by hyperglycemia. Evaluate the efficacy of glimepiride and teneligliptin in combination with metformin in type-2 diabetes mellitus (2DM) patients uncontrolled with metformin alone. 60 Type-2 DM patients uncontrolled with metformin mono therapy were enrolled and divided in to 2 groups, group-A and group-B, 30 patients each. After taking history and concern, the clinical examination and biochemical investigations including HbA1c, fasting plasma glucose (FPG), post prandial plasma glucose (PPPG) were done, followed by group-A patients were given glimepiride 1mg/OD and metformin 500 mg/BD after major meal for 3 months where as group-B patients were given teneligliptin 20mg/OD and metformin 500mg/BD after major meal for 3 months. FPG, PPPG was done every week for 3 months and HbA1c was repeated at 3 rd month. Data was collected and analyzed using SPSS software and results were expressed as Mean ± SD. A significant decrease in HbA1c, FPG and PPPG was observed in both group A and group B after 4 th , 8 th and 12 th week of study when compared with baseline values, but high mean reduction of HbA1c, FPG and PPPG was observed in group-B as compared to group-A. Teneligliptin and Metformin had shown better improvement on glycemic control as compared to glimepiride and metformin. The efficacy of teneligliptin is more than glimepiride.

show abstract

Section: Discussionsupporting

confidence: 92%

Efficacy Of Dual Drug Therapy In Type-2 Diabetes Mellitus Patients Uncontrolled With Metformin Monotherapy (2023)

2023

jcdr

View full text Add to dashboard Cite

show abstract

“…Data from real-world, retrospective study (Treat-India) suggests that Teneligliptin significantly (p < 0.001) improves glycemic control in T2DM patients, when prescribed either as monotherapy or in combination with Metformin compared with SU combination therapy. [ 62 63 ]…”

Section: Purpose Of the Expert Opinionmentioning

confidence: 99%

Optimizing the treatment of newly diagnosed type 2 diabetes mellitus with combination of dipeptidyl peptidase-4 inhibitors and metformin

Das

Gandhi²,

Saboo

et al. 2021

Journal of Family Medicine and Primary Care

View full text Add to dashboard Cite

The expanding burden of Type 2 Diabetes Mellitus (T2DM) in today's world, with respect to incidence, prevalence, and cost incurred, is an existential risk to society. Various guidelines recommend individualization of treatment. This expert opinion aims to review the recent evidences and reach a consensus on the preferable combination therapy for use in newly diagnosed Indian T2DM patients with HbA 1C >7.5%. The core committee included seventeen diabetes specialists. Three statements were developed, discussed, and rated by specialists and recommendations were noted. Specialists were requested to rate the statements using a 9-point Likert's scale with score of 1 being “Strongly Disagree” and 9 being “Strongly Agree”. Statement-specific scores of all the specialists were added and mean score of ≥7.00 was considered to have achieved a consensus. Statements used to meet the consensus were: Statement 1. Majority of newly-diagnosed Indian diabetics have HbA 1C >7.5%; Statement 2. Patients with HbA 1C >7.5% may be initiated with dual therapy of dipeptidyl peptidase-4 inhibitors (DPP4Is) + Metformin; and Statement 3. In Indian patients with HbA 1C >7.5% at diagnosis, DPP4Is + Metformin may be considered as a first-line therapy. Literature review revealed that HbA 1C level at the time of diagnosis in majority of Indian T2DM patients is >7.5%. Consensus was reached that dual anti-diabetic therapy should be initiated in patients with HbA 1C >7.5%. DPP4Is + Metformin is the preferred cost-effective option and may be considered as a first-line therapy in Indian T2DM patients with HbA 1C >7.5% at diagnosis.

show abstract

Determining the Efficacy and Safety of Teneligliptin and Metformin Versus Glimepiride and Metformin in Patients of Type-2 Diabetes Mellitus Uncontrolled with Monotherapy

Hans

2021

Technological Innovation in Pharmaceutical Research Vol. 10

View full text Add to dashboard Cite

Patients characteristics associated with better glycemic response to teneligliptin and metformin therapy in type 2 diabetes: a retrospective study

Cited by 3 publications

References 13 publications

Efficacy Of Dual Drug Therapy In Type-2 Diabetes Mellitus Patients Uncontrolled With Metformin Monotherapy (2023)

Efficacy Of Dual Drug Therapy In Type-2 Diabetes Mellitus Patients Uncontrolled With Metformin Monotherapy (2023)

Optimizing the treatment of newly diagnosed type 2 diabetes mellitus with combination of dipeptidyl peptidase-4 inhibitors and metformin

Determining the Efficacy and Safety of Teneligliptin and Metformin Versus Glimepiride and Metformin in Patients of Type-2 Diabetes Mellitus Uncontrolled with Monotherapy

Contact Info

Product

Resources

About